NO20063951L - Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom - Google Patents

Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom

Info

Publication number
NO20063951L
NO20063951L NO20063951A NO20063951A NO20063951L NO 20063951 L NO20063951 L NO 20063951L NO 20063951 A NO20063951 A NO 20063951A NO 20063951 A NO20063951 A NO 20063951A NO 20063951 L NO20063951 L NO 20063951L
Authority
NO
Norway
Prior art keywords
methods
preparations
metastatic disease
immunoglobulins
treating tumors
Prior art date
Application number
NO20063951A
Other languages
English (en)
Inventor
Nancy Wehner
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20063951L publication Critical patent/NO20063951L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparater, fremgangsmåter og kombinasjonsterapier til behandlingen av lymfomer, leukemier, melanomer, prostatakreft og metastatisk sykdom blir tilveiebrakt. Spesifikt blir preparater som omfatter anti-a-integrinimmunoglobuliner eller immunoglobuliner som binder til en aintegrinligand (f.eks. MadCAM-1 og VCAM-1) tilkjennegj ort til anvendelse for å inhibere tumorvekst og progresjon og inhibering av metastaser. Et foretrukket immunoglobulin til anvendelse for å behandle tumorer og metastaser er natalizumab. Preparatene og fremgangsmåtene som benytter disse immunoglobulinene kan bli benyttet alene eller i kombinasjon med andre reagenser og kreftbehandlingsmodaliteter.
NO20063951A 2004-02-06 2006-09-05 Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom NO20063951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54194604P 2004-02-06 2004-02-06
PCT/US2005/002860 WO2005076843A2 (en) 2004-02-06 2005-02-03 Methods and compositions for treating tumors and metastatic disease

Publications (1)

Publication Number Publication Date
NO20063951L true NO20063951L (no) 2006-11-02

Family

ID=34860234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063951A NO20063951L (no) 2004-02-06 2006-09-05 Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom

Country Status (19)

Country Link
US (1) US20050255118A1 (no)
EP (2) EP2394652A3 (no)
JP (1) JP4996261B2 (no)
KR (1) KR20070009581A (no)
CN (1) CN1946407B (no)
AR (1) AR047534A1 (no)
AU (1) AU2005213324B2 (no)
BR (1) BRPI0507451A (no)
CA (1) CA2555365A1 (no)
EA (1) EA009873B1 (no)
IL (1) IL177201A0 (no)
MX (1) MXPA06008746A (no)
NO (1) NO20063951L (no)
NZ (1) NZ584288A (no)
PE (1) PE20060009A1 (no)
TW (1) TWI375563B (no)
UY (1) UY28741A1 (no)
WO (1) WO2005076843A2 (no)
ZA (1) ZA200606557B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
JP2011506322A (ja) * 2007-12-07 2011-03-03 エラン ファーマシューティカルズ，インコーポレイテッド 液性腫瘍を治療するための方法および組成物
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
US20110110940A1 (en) * 2008-04-15 2011-05-12 Oxigene, Inc. Methods for Enhancing the Efficacy of Vascular Disrupting Agents
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
BRPI1011389A2 (pt) * 2009-04-17 2018-07-10 Biogen Idec Inc método para tratar a leucemia mielógena aguda (aml) em um paciente
US20110158982A1 (en) * 2009-10-05 2011-06-30 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
HUE050713T2 (hu) 2010-10-25 2020-12-28 Biogen Ma Inc Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával
CA2842443C (en) 2011-07-22 2022-01-25 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
US12194002B2 (en) 2011-08-17 2025-01-14 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
WO2014018913A2 (en) * 2012-07-27 2014-01-30 University Of Connecticut Santacruzamate a compositions and analogs and methods of use
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
RU2527154C1 (ru) * 2013-03-27 2014-08-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ повышения биодоступности цисплатина в саркому -45, индуцированную в эксперименте
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US20160333108A1 (en) 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
CN106659716B (zh) 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
CA2966334A1 (en) 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
RU2650587C1 (ru) * 2017-04-26 2018-04-16 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ модификации хронической болью злокачественного роста меланомы в16 у мышей
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
US20210338727A1 (en) * 2018-09-13 2021-11-04 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
RU2765955C1 (ru) * 2021-03-30 2022-02-07 Елена Рудольфовна Милаева Средство для ингибирования метастазирования в легких
RU2762730C1 (ru) * 2021-03-30 2021-12-22 Елена Рудольфовна Милаева Средство для ингибирования метастазирования в легких
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
EP1019064A4 (en) * 1997-02-28 2006-11-08 Univ California Inhibition of cell-cell binding by lipid assemblies
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
EP2065050A1 (en) * 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
JP2003517023A (ja) 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
EP1401484A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
AU2002356180A1 (en) * 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005044998A2 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody

Also Published As

Publication number Publication date
IL177201A0 (en) 2006-12-10
EA200601433A1 (ru) 2007-02-27
EP2394652A3 (en) 2012-10-24
NZ584288A (en) 2011-10-28
AU2005213324A1 (en) 2005-08-25
ZA200606557B (en) 2008-02-27
MXPA06008746A (es) 2007-01-23
EA009873B1 (ru) 2008-04-28
WO2005076843A3 (en) 2006-01-26
EP1718310A4 (en) 2009-05-06
AR047534A1 (es) 2006-01-25
EP1718310A2 (en) 2006-11-08
CN1946407B (zh) 2011-10-05
TW200536556A (en) 2005-11-16
TWI375563B (en) 2012-11-01
KR20070009581A (ko) 2007-01-18
US20050255118A1 (en) 2005-11-17
AU2005213324B2 (en) 2011-06-09
JP4996261B2 (ja) 2012-08-08
EP2394652A2 (en) 2011-12-14
PE20060009A1 (es) 2006-02-11
WO2005076843A2 (en) 2005-08-25
BRPI0507451A (pt) 2007-07-10
CA2555365A1 (en) 2005-08-25
JP2007520557A (ja) 2007-07-26
CN1946407A (zh) 2007-04-11
UY28741A1 (es) 2005-08-31

Similar Documents

Publication Publication Date Title
NO20063951L (no) Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom
Parisotto et al. Genetically engineered mouse models of prostate cancer
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
MX373790B (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
ATE546158T1 (de) Therapeutisches krebsmittel mit polymergebundenem antikörper
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EA201992575A1 (ru) Биомаркеры для терапии рака
ATE531388T1 (de) Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
EA201391423A1 (ru) Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
BR112022009223A2 (pt) Moléculas de anticorpo anti-siglec-9
DE60030696D1 (de) Spezifische antikörper für cyp1b1
Yajima et al. Anti-androgen therapy for the patients with recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors: a retrospective study
Mantell et al. In vivo activity of humanized monoclonal anti-EGFR antibody EMD 72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model
ATE461706T1 (de) Verwendung eines antikörpers anti-pthrp(34-53) als antagonist von pthrp zur behandlung von nierenzellkarzinoma
Lagenfelt et al. Real-world evidence on second line chemotherapy in advanced biliary tract carcinoma refractory to gemcitabine and oxaliplatin (GemOx)
Paholak Nanoparticle Design and Novel Approaches to Enhance Photothermal Cancer Therapy.
Królicki et al. Secondary glioblastoma multiforme–local alpha emitters targeted therapy with 213Bi-DOTA-substance P
Mahteme Hepatic and peritoneal colorectal metastases: Aspects of prognosis and treatment.
Rahvar et al. Study of GBP2 Gene Expression and Its Promoter Methylation Pattern in Tumors of Breast Cancer Patients
Moiseenko et al. ANATOMICAL LANDMARKS FOR ROBOTIC NERVE SPARING RADICAL PROSTATECTOMY
Moore The Role of EZH2 in Breast Cancer Progression and Metastasis.
Burgess Can vitamin C reduce metastasis in a mouse model of breast cancer?
Hattier et al. Optimizing vaccine immunotherapy for prostate cancer
Schindlbeck et al. Thomsen-Friedenreich Antigen–Prognostic Factor in Primary Breast Cancer Tissue, Expression on Disseminated Tumor Cells and Target for Immunomagnetic Enrichment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application